Surgical WoundPROMISESNCT03274466
Closed Incision Negative Pressure Therapy Versus Standard of Care Surgical Dressing in Revision Total Knee Arthroplasty
A study testing Closed Incision Negative Pressure Therapy (ciNPT) in people with Surgical Wound and Revision Total Knee Arthroplasty, run by KCI USA, Inc at 17 sites in United States.
Trial summary
This study evaluates surgical site complications in subjects undergoing revision of a total knee arthroplasty when closed incision negative pressure therapy is used to manage the closed incision, as compared to a standard of care dressing. Read more about this study
- Who is it for?
- Ages 22 years and older
- Conditions the study is for
- Surgical Wound, Revision Total Knee Arthroplasty, Wounds and Injuries
- What is being tested?
- Closed Incision Negative Pressure Therapy (ciNPT)
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 294 participants
- Where
- 17 sitesUnited States
- Study dates
- 5 Dec 2017to 19 Dec 2019
- Phase
- Interventional
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 22 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Pre-operative Inclusion Criteria:
The subject:
- is at least 22 years of age on the date of informed consent
- is able to provide their own informed consent
- requires a TKA revision defined as one of the following:
- a one-stage aseptic revision procedure
- a one-stage septic exchange procedure (requiring removal of all hardware) for acute postoperative infection
- removal of cement spacer and re-implantation procedure
- open reduction and internal fixation of peri-prosthetic fractures
- has one or more of the following:
- a body mass index (BMI) greater than 35 kg/m2
- a requirement for the use of blood thinners other than acetylsalicylic acid (ASA) after surgery
- history of or current peripheral vascular disease
- the presence of lymphedema in the operative limb
- insulin-dependent diabetes mellitus
- current tobacco use or previous history of smoking and quitting within the past 30 days
- a history of prior infection of the operative site
- current use of immunomodulators or steroids
- current or history of cancer or hematological malignancy (excluding localized skin cancer)
- rheumatoid arthritis
- current renal failure or dialysis
- malnutrition as determined by the investigator
- liver disease as determined by the investigator
- status post solid organ transplant
- HIV
- is willing and able to return for all scheduled study visits
- if female, has a negative urine or serum pregnancy test at screening and day of revision surgery. Women who have had surgical sterilization by a medically accepted method such as tubal ligation, hysterectomy, or oophorectomy or are post-menopausal, defined as not having menstruation for >= 12 months will be excluded from requiring this test.
Intra-operative Inclusion Criteria:
The subject:
- continues to meet all pre-operative inclusion criteria
- has undergone a TKA revision resulting in a closed surgical incision
Pre-operative Exclusion Criteria:
The subject:
- is pregnant or lactating
- will undergo a bilateral TKA within the same operative visit
- will undergo a bilateral TKA in which the first TKA surgery is on the knee selected for study
- will undergo a staged bilateral TKA in which the TKA revision surgery for the knee under study occurs within 30 days of the first TKA procedure
- was previously randomized in this protocol
- has a systemic active infection at the time of revision not including chronic viral infections such as HIV or hepatitis
- has a remote-site skin infection at the time of revision
- was tattooed on the area of the incision within 30 days prior to randomization
- has known sensitivity to the study product components (drape and/or dressing materials in direct contact with the closed incision or skin)
- has known sensitivity to silver
- is currently enrolled in another investigational trial that requires additional interventions
- is planned to be enrolled in another investigational trial that requires additional interventions at any time during the study
- has localized skin cancer around the incision site
Intra-operative Exclusion Criteria:
The subject:
- is found to meet any of the pre-operative exclusion criteria
- has a surgical incision that precludes placement of dressing
- has a TKA revision resulting in a muscle flap
- has a TKA revision resulting in the placement of a spacer
- has an incision drainage and debridement procedure only
- has a surgical incision closed with skin glue
Trial locations and contacts
17 sites in 1 country.
17 sites in 1 country
United States17 sites
Northwell Health - SouthSide Hospital
Bay Shore, New York, 11706
Cleveland Clinic
Cleveland, Ohio, 44195
University of Missouri Health Care
Columbia, Missouri, 65212
Duke University Medical Center
Durham, North Carolina, 27705
Houston Methodist Research Institute
Houston, Texas, 77030
Joint Implant Surgeons
New Albany, Ohio, 43054
LSU Health Science Center
New Orleans, Louisiana, 70006
New York University (NYU)
New York, New York, 10003
Hospital for Special Surgery
New York, New York, 10021
Columbia University Medical Center/New York Presbyterian Hospital
New York, New York, 10032
Northwell Health - Lenox Hill Hospital
New York, New York, 10075
University of Pennsylvania
Philadelphia, Pennsylvania, 19104
Rothman Institute - Thomas Jefferson University Hospital
Philadelphia, Pennsylvania, 19107
Oregon Health & Science University
Portland, Oregon, 97239
Virginia Commonwealth University
Richmond, Virginia, 32743
Emory University Orthopedics & Spine Hospital
Tucker, Georgia, 30084
Cleveland Clinic
Weston, Florida, 33331
About this study
Official title: Post-market, Randomized, Open-Label, Multicenter, Study to Evaluate the Effectiveness of Closed Incision Negative Pressure Therapy Versus Standard of Care Dressings in Reducing Surgical Site Complications in Subjects With Revision of a Failed Total Knee Arthroplasty (PROMISES)
This study evaluates surgical site complications in subjects undergoing revision of a total knee arthroplasty when closed incision negative pressure therapy is used to manage the closed incision, as compared to a standard of care dressing.
- Conditions
- Surgical Wound, Revision Total Knee Arthroplasty, Wounds and Injuries, Joint Disease, Musculoskeletal Disease, Prosthesis-Related Infections
- Being tested
- Closed Incision Negative Pressure Therapy (ciNPT), Standard of Care Dressing
- Medical subject headings
- Surgical Wound, Wounds and Injuries, Joint Diseases, Musculoskeletal Diseases, Prosthesis-Related Infections, Infections, Postoperative Complications, Pathologic Processes
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Closed Incision Negative Pressure Therapy (ciNPT)Device
Also called Prevena Peel & Place, Prevena Plus Customizable, ActiV.A.C. Therapy Unit, Prevena Plus 125 Therapy Unit
Closed Incision Negative Pressure Therapy applied through a foam bolster with a wicking interface fabric that includes 0.019% ionic silver at 125 mmHg of negative pressure for 5-7 days.
Standard of Care DressingDevice
Also called Silver-impregnated dressing, Aquacel Ag Surgical or other equivalent
A standard silver-impregnated dressing applied to a closed surgical incision for 5-7 days post-operatively.
| Study group | Role | What they receive |
|---|---|---|
| Closed Incision Negative Pressure Therapy (ciNPT) | Experimental | Prevena Peel \& Place or Prevena Plus Customizable Dressing and ActiVAC Therapy Unit or Prevena Plus Therapy Unit Receives: Device: Closed Incision Negative Pressure Therapy (ciNPT) |
| Standard of Care Dressing | Active comparator | Silver impregnated dressing Receives: Device: Standard of Care Dressing |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of Participants With Surgical Site Complications (SSC)
The subject incidence of Investigator-assessed surgical site complications (SSCs) within 90 days of TKA revision. SSCs include any of the following:
- Superficial Surgical Site Infection (SSI)
- Deep SSI
- Full thickness skin dehiscence
- Seroma or hematoma requiring drainage or surgery
- Skin necrosis
- Continued drainage at the time of dressing removal
Measured: within 90 days after TKA revision
Secondary outcomes (2)
Number of Participants With Surgical Site Infection (SSI) (Superficial or Deep)
90 day subject incidence of any SSI (superficial or deep)
Measured: 90 days after TKA revision
Number of Participants With Deep Surgical Site Infection
90 day subject incidence of deep surgical site infection
Measured: 90 days after TKA revision
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Sep 2017
- Study start5 Dec 2017
- Primary completion27 Nov 2019
- Study completion19 Dec 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Surgical WoundStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 294 participants (actual)
Sponsor and investigators
- Lead sponsor
- KCI USA, Inc
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- 3M
- Responsible party
- Sponsor
- Investigators
- Carlos Higuera, MD, Principal investigator, The Cleveland Clinic
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03274466
- Sponsor's protocol ID
- KCI.PREVENA.2017.01
- Acronym
- PROMISES
- Status last verified
- Oct 2024
- First submitted
- 5 Sep 2017
- Last updated
- 16 Oct 2024
- Results posted
- Yes, on ClinicalTrials.gov
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 16 Oct 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Post-market, Randomized, Open-Label, Multicenter, Study to Evaluate the Effectiveness of Closed Incision Negative Pressure Therapy Versus Standard of Care Dressings in Reducing Surgical Site Complications in Subjects With Revision of a Failed Total Knee Arthroplasty (PROMISES)
- ClinicalTrials.gov ID
- NCT03274466
- Acronym / sponsor ID
- PROMISES / KCI.PREVENA.2017.01
- Conditions
- Surgical Wound, Revision Total Knee Arthroplasty, Wounds and Injuries, Joint Disease, Musculoskeletal Disease, Prosthesis-Related Infections
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 294 participants (actual)
- Lead sponsor
- KCI USA, IncIndustry (pharma, biotech, devices)
- Collaborators
- 3M
- Study start
- 5 Dec 2017 (actual)
- Primary completion
- 27 Nov 2019 (actual)
- Study completion
- 19 Dec 2019 (actual)
- First posted
- 7 Sep 2017 (actual)
- Results
- Posted 10 Feb 2021
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study evaluates surgical site complications in subjects undergoing revision of a total knee arthroplasty when closed incision negative pressure therapy is used to manage the closed incision, as compared to a standard of care dressing.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Closed Incision Negative Pressure Therapy (ciNPT) | Experimental | Device: Closed Incision Negative Pressure Therapy (ciNPT)Prevena Peel \& Place or Prevena Plus Customizable Dressing and ActiVAC Therapy Unit or Prevena Plus Therapy Unit |
| Standard of Care Dressing | Active comparator | Device: Standard of Care DressingSilver impregnated dressing |
Who may qualify
- Ages
- 22 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Closed Incision Negative Pressure Therapy (ciNPT)Also: Prevena Peel & Place, Prevena Plus Customizable, ActiV.A.C. Therapy Unit, Prevena Plus 125 Therapy UnitClosed Incision Negative Pressure Therapy applied through a foam bolster with a wicking interface fabric that includes 0.019% ionic silver at 125 mmHg of negative pressure for 5-7 days. | Device | Closed Incision Negative Pressure Therapy (ciNPT) |
| Standard of Care DressingAlso: Silver-impregnated dressing, Aquacel Ag Surgical or other equivalentA standard silver-impregnated dressing applied to a closed surgical incision for 5-7 days post-operatively. | Device | Standard of Care Dressing |
Primary outcome
Number of Participants With Surgical Site Complications (SSC)
Time frame: within 90 days after TKA revision
The subject incidence of Investigator-assessed surgical site complications (SSCs) within 90 days of TKA revision. SSCs include any of the following: * Superficial Surgical Site Infection (SSI) * Deep SSI * Full thickness skin dehiscence * Seroma or hematoma requiring drainage or surgery * Skin necrosis * Continued drainage at the time of dressing removal
2 secondary outcomes
Number of Participants With Surgical Site Infection (SSI) (Superficial or Deep)
Time frame: 90 days after TKA revision
Number of Participants With Deep Surgical Site Infection
Time frame: 90 days after TKA revision
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Oct 2024.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
Related trials for Surgical Wound
Not yet recruiting
Safety Study of Microlyte DualGuard
Wound Closure, Wound Care
Not yet recruitingPhase 4
Roxadustat and Myocardial Injury After Off-Pump Coronary Artery Bypass Surgery
Coronary Artery Disease, Coronary Artery Bypass Grafting
Recruiting
SIRI Levels Following PENG Block in Pediatric Hip Surgery
Hip Dysplasia
RecruitingPhase 4
PENG With LFCB vs. ESP Blocks for Pediatric Hip Surgery
Hip Disease, Hip Dysplasia
Not yet recruiting
Biodegradable Magnesium Screws for Unstable Ankle Fracture Surgery
Ankle Fractures, Syndesmotic Injury
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Carlos Higuera, MD principal investigator
The Cleveland Clinic
17 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Closed Incision Negative Pressure Therapy (ciNPT) in people with Surgical Wound and Revision Total Knee Arthroplasty, run by KCI USA, Inc at 17 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 16 Oct 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 17 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 10 Feb 2021). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of Participants With Surgical Site Complications (SSC) (time frame: within 90 days after TKA revision). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Oct 2024.